ACG Clinical Guideline: Alcoholic Liver Disease

HepatitisHepatology

Diagnosis and Treatment of Alcohol-Related Liver Diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases

Hepatology.

Crabb DW, Im GY, Szabo G, Mellinger JL, Lucey MR

doi: 10.1002/hep.30866.

HepatitisHepatology

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Lancet Gastroenterol Hepatol.

Nguyen-Khac E, Thiele M, Voican C, Nahon P, Moreno C, Boursier J, Mueller S, de Ledinghen V, Stärkel P, Gyune Kim S, Fernandez M, Madsen B, Naveau S, Krag A, Perlemuter G, Ziol M, Chatelain D, Diouf M

doi: 10.1016/S2468-1253

Hepatology

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

J Gastroenterol Hepatol.

Yamamura S, Nakano D, Hashida R, Tsutsumi T, Kawaguchi T, Okada M, Isoda H, Takahashi H, Matsuse H, Eguchi Y, Sumida Y, Nakajima A, Gerber L, Younossi ZM, Torimura T

doi: 10.1111/jgh.15172.

Hepatology

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

BMC Gastroenterol.

Trembling PM, Apostolidou S, Gentry-Maharaj A, Parkes J, Ryan A, Tanwar S, Burnell M, Harris S, Menon U, Rosenberg WM

doi: 10.1186/s12876-020-01251-w.

Gastrointestinal Diseases

Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral

Lancet Gastroenterol Hepatol

Masson S, Aldersley H, Leithead JA, Day E, Langford A, Healy P, O'Grady J, Thorburn D, Parker C, Shepherd L, Arndtz K, Webb K, Holt A

doi: 10.1016/S2468-1253(21)00195-3

Hepatology

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

BMC Gastroenterol.

Liang Y, Li D

doi: 10.1186/s12876-020-01234-x.

Hepatology

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Liver Transpl

Younossi ZM

doi: 10.1002/lt.25003.

Hepatology

Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease

Hepatology.

Wang M, Chen WY, Zhang J, Gobejishvili L, Barve SS, McClain CJ, Joshi-Barve S

doi: 10.1002/hep.31197.

Hepatology

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease

J Hepatol.

Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V

doi: 10.1016/j.jhep.2019.12.008.

Related content

Diagnosis and Treatment of Alcohol-Related Liver Diseases: 2019 Practice Guidance from the American Association for the Study of Liver Diseases

Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis

Patient-reported Outcomes (PROs) in Patients with Non-alcoholic Fatty Liver Disease: A Narrative Review of CLDQ-NAFLD/NASH

The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease

Liver transplantation for alcohol-related liver disease in the UK: revised UK Liver Advisory Group recommendations for referral

Magnetic resonance elastography in staging liver fibrosis in non-alcoholic fatty liver disease: a pooled analysis of the diagnostic accuracy

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation

Elevated fructose and uric acid via aldose reductase contribute to experimental and human alcoholic liver disease

Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease